Certificate in Psychedelic-Assisted Therapies (CPAT)
Training Program
Live
May 01, 2024
8,250
–
9,250
AUD
Hybrid
4 Months
Awarded: Certificate, Psychedelic-Assisted Therapies
Description
Mind Medicine Australia (MMA) is a charity that seeks to alleviate the suffering caused by mental illness in Australia through expanding the treatment options available to medical practitioners and their patients. We are focused on the development of safe and effective psychedelic-assisted therapies to cure a range of mental illnesses.
To this end, MMA has developed the Certificate in Psychedelic-Assisted Therapies (CPAT) in collaboration with leading PAT practitioners in the USA and UK.
The MMA CPAT will give qualified clinicians the additional skills and awareness they need in order to safely and successfully facilitate PAT. Instruction will focus on a standardized approach to PAT that can be integrated with clinicians’ existing psychotherapeutic experience and training. The CPAT will include a mix of face-to-face, self-study and online learning components.
The course has been developed specifically with the objective of providing the clinical training necessary for existing qualified psychiatrists, psychologists, psychotherapists, GPs, physicians, mental health nurses, social workers, occupational therapists, drug and addiction specialists to work with patients utilising psilocybin and MDMA therapeutically in clinical environments.
With the recent announce by the TGA, of the limited rescheduling of psilocybin and MDMA, psychedelic-assisted therapies will be accessible in Australia outside of clinical trials for the first time from July 1 2023.
To this end, MMA has developed the Certificate in Psychedelic-Assisted Therapies (CPAT) in collaboration with leading PAT practitioners in the USA and UK.
The MMA CPAT will give qualified clinicians the additional skills and awareness they need in order to safely and successfully facilitate PAT. Instruction will focus on a standardized approach to PAT that can be integrated with clinicians’ existing psychotherapeutic experience and training. The CPAT will include a mix of face-to-face, self-study and online learning components.
The course has been developed specifically with the objective of providing the clinical training necessary for existing qualified psychiatrists, psychologists, psychotherapists, GPs, physicians, mental health nurses, social workers, occupational therapists, drug and addiction specialists to work with patients utilising psilocybin and MDMA therapeutically in clinical environments.
With the recent announce by the TGA, of the limited rescheduling of psilocybin and MDMA, psychedelic-assisted therapies will be accessible in Australia outside of clinical trials for the first time from July 1 2023.
